To Investigate the Effects of Empagliflozin Combined with Insulin Degludec on Glucose and Lipid Metabolism and Islet β Cell Function in Patients with Type 2 Diabetes Mellitus
Objective To investigate the effects of empagliflozin combined with insulin degludec on glucose and lipid metabolism and islet β cell function in patients with type 2 diabetes mellitus(T2DM).Methods 88 patients with T2DM admitted to Xunyang District People's Hospital from October 2021 to December 2022 were divided into two groups using a random number table method,with 44 patients in each group.The control group was treated with insulin degludec,and the study group was treated with empagliflozin on the basis of the control group.Compare the clinical efficacy,blood glucose metabolism indicators,blood lipid metabolism indicators,and pancreatic islets between two groups β cellular function indicators(insulin secretion index HOMA-β),β cell function index(MBCI),insulin resistance index(HOMA-IR),serum factors[serum atrial natriuretic peptide(ANP),endothelin-1(ET-1),matrix metalloproteinase-9(MMP-9),malondialdehyde(MDA)]levels,and incidence of adverse reactions.Results The total clinical rate of the study group was higher than that of the control group(P<0.05).After treatment,the blood glucose metabolism index of the study group was lower than that of the control group(P<0.05);the levels of high-density lipoprotein cholesterol(HDL-C)in the study group were higher than those in the control group,while the levels of low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC),and triglycerides(TG)were lower than those in the control group(P<0.05);HOMA-β,MBCI were higher than in the control group,while HOMA-IR was lower than the control group(P<0.05);Comparison of incidence of adverse reactions between groups(P>0.05).Conclusion Empagliflozin combined with insulin degludec in the treatment of T2DM can enhance the efficacy,correct glucose and lipid metabolism disorders,improve islet β cell function,relieve endothelial injury and oxidative stress injury,and has high drug safety.
Type 2 diabetes mellitusEmpagliflozinInsulin degludecGlucose and lipid metabolism indicatorsIslet β cell functionInsulin resistance
NETL
NSTL
万方数据
